دورية أكاديمية
أعرض في EDS

Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database.

التفاصيل البيبلوغرافية
العنوان: Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database.
المؤلفون: Keizman D; Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Fosboel MO; Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Reichegger H; Department of Oncology and Haematology, Kantonsspital St Gallen, St Gallen, Switzerland.; Department of Radiology and Nuclear Medicine, Kantonsspital St Gallen, St Gallen, Switzerland., Peer A; Department of Oncology, Rambam Medical Center, Haifa, Israel., Rosenbaum E; Department of Oncology, Rabin Medical Center, Petah Tikva, Israel., Desax MC; Department of Oncology and Haematology, Kantonsspital St Gallen, St Gallen, Switzerland.; Department of Radiology and Nuclear Medicine, Kantonsspital St Gallen, St Gallen, Switzerland., Neiman V; Department of Oncology, Rabin Medical Center, Petah Tikva, Israel., Petersen PM; Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Mueller J; Department of Oncology and Haematology, Kantonsspital St Gallen, St Gallen, Switzerland.; Department of Radiology and Nuclear Medicine, Kantonsspital St Gallen, St Gallen, Switzerland., Cathomas R; Department of Oncology, Kantonsspital Chur, Chur, Switzerland., Gottfried M; Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Dresler H; Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Sarid D; Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel., Mermershtain W; Department of Oncology, Soroka Medical Center, Beer-Sheva, Israel., Rouvinov K; Department of Oncology, Soroka Medical Center, Beer-Sheva, Israel., Mortensen J; Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Gillessen S; Department of Oncology and Haematology, Kantonsspital St Gallen, St Gallen, Switzerland.; Department of Radiology and Nuclear Medicine, Kantonsspital St Gallen, St Gallen, Switzerland., Daugaard G; Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Omlin A; Department of Oncology and Haematology, Kantonsspital St Gallen, St Gallen, Switzerland.; Department of Radiology and Nuclear Medicine, Kantonsspital St Gallen, St Gallen, Switzerland.
المصدر: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2017 Sep; Vol. 20 (3), pp. 289-293. Date of Electronic Publication: 2017 Feb 28.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9815755 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5608 (Electronic) Linking ISSN: 13657852 NLM ISO Abbreviation: Prostate Cancer Prostatic Dis Subsets: MEDLINE
أسماء مطبوعة: Publication: <2002->: London : Nature Publishing Group
Original Publication: Houndmills, Basingstoke, UK : Stockton Press, c1997-
مواضيع طبية MeSH: Bone Neoplasms/*radiotherapy , Prostatic Neoplasms, Castration-Resistant/*radiotherapy , Radiopharmaceuticals/*therapeutic use , Radium/*therapeutic use, Aged ; Aged, 80 and over ; Bone Neoplasms/diagnostic imaging ; Bone Neoplasms/secondary ; Humans ; Kallikreins/blood ; Male ; Middle Aged ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms, Castration-Resistant/diagnostic imaging ; Prostatic Neoplasms, Castration-Resistant/pathology ; Retrospective Studies ; Treatment Outcome
مستخلص: Background: The imaging response to radium-223 therapy is at present poorly described. We aimed to describe the imaging response to radium-223 treatment.
Methods: We retrospectively evaluated the computed tomography (CT) and bone scintigraphy response of metastatic castration-resistant prostate cancer (CRPC) patients treated with radium-223, in eight centers in three countries.
Results: A total of 130 patients were included, the majority (n=84, 65%) received radium-223 post docetaxel. Thirty-four of 99 patients with available data (34%) received concomitant abiraterone or enzalutamide. A total of 54% (n=70) patients completed the planned six injections of radium-223. In patients with available data, a transient increase in bone metastases-related pain was observed in 27% (n=33/124) and an improvement of bone metastases-related pain on treatment with radium-223 was noted in 49% of patients (n=61/124). At 3 and 6 months of treatment with radium-223, bone imaging showed stable disease in 74% (n=84/113) and 94% of patients (n=93/99) with available data, respectively. An increase in the number of bone lesions was documented at 3 months compared with baseline in 26% (n=29/113) and at 6 months compared with 3 months in 6% of patients (n=6/99), respectively. Radiological extraskeletal disease progression occurred in 46% of patients (n=57/124) with available CT data at 3 and/or 6 months.
Conclusions: Progression of bone metastases during radium-223 therapy is uncommon. A bone flare (pain and/or radiological) may be noted during the first 3 months, and should not be confused with progression. Imaging by CT scan should be considered after three and six doses of radium-223 to rule out extraskeletal disease progression.
المشرفين على المادة: 0 (Radiopharmaceuticals)
8BR2SOL3L1 (Radium-223)
EC 3.4.21.- (KLK3 protein, human)
EC 3.4.21.- (Kallikreins)
EC 3.4.21.77 (Prostate-Specific Antigen)
W90AYD6R3Q (Radium)
تواريخ الأحداث: Date Created: 20170301 Date Completed: 20180515 Latest Revision: 20211122
رمز التحديث: 20221213
DOI: 10.1038/pcan.2017.6
PMID: 28244493
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-5608
DOI:10.1038/pcan.2017.6